Stem Cell/Cord Blood Banking Global Market Report 2023 – By Bank Type (Public, Private), By Service (Collection, Processing, Analysis, Storage), By Application (Leukemia, Anemia, Thalassemia, Autism, Cerebral Palsy, Diabetes, Other Applications), By Cell Type (Adult Stem Cells, Umbilical Cord Blood Stem Cells, Embryonic Stem Cells) – Market Size, Trends, And Global Forecast 2023-2032

Stem cells are autologous or allogenic cells that can differentiate into various types of cells in vivo and in vitro.They aid in medical treatment of injuries and organ damage. The main product types of stem cell are adult stem cell, human embryonic stem cell, induced pluripotent stem cell and others. Adult stem cells are a rare population of cells found in the body for the majority of postnatal life that give rise to a limited number of mature cell types that form the tissue in which they dwell. The different sources include autologous, allogeneic and are used in various applications such as regenerative medicine, drug discovery, and development. The global stem cell market is segmented - 1) By Source: Autologous, Allogeneic 2) By Product Type: Adult Stem Cell, Human Embryonic Stem Cell, Induced Pluripotent Stem Cell, Other Products 3) By Application: Regenerative Medicine, Drug Discovery And Development The global stem cell market grew from $12.72 billion in 2022 to $13.97 billion in 2023 at a compound annual growth rate (CAGR) of 9.8%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The stem cell market is expected to grow from $20.67 billion in 2027 at a CAGR of 10.3%. There is an increase in the prevalence of Chronic diseases worldwide which drives the Stem cell market. Stem-cell therapy is the use of stem cells to treat or prevent a disease or condition. Bone marrow transplant is the most widely used stem-cell therapy, but some therapies derived from umbilical cord blood are also in use. Currently, widely used stem cell treatment is the transplantation of blood stem cells to treat diseases and conditions of the blood and immune system, or to restore the blood system after treatments for specific cancers. According to WHO, in 2020, prevalence of chronic disease increased to 57%. As the prevalence of chronic disease increases, people opting for the stem cell-based treatment will rise, thus driving the market going forward. Currently, approximately 26,000 patients are treated with blood stem cells in Europe each year. Major players in the stem cell market are Anterogen Co., Ltd., Mesoblast Ltd., Osiris TherapeuticsInc., AlloSource, Cellular Engineering Technologies, BIOTIMEInc., Astellas Pharma USInc., Vericel, RTI SurgicalInc. and Takara Bio Company. The low acceptance rate for stem cell therapy treatments is restraining the growth of the stem cell market. The acceptance rate is particularly low in the Embryonic stem cell therapeutics. Most of these stem cell therapies are yet to be proven in clinical trials and are highly experimental. Due to the nature of these unproven treatments, patients are reluctant to take up these therapies as they present serious health, personal and financial issues. For example, if a person undergoes an unproven or experimental treatment it might make that person ineligible for future clinical trials or treatment options. For instance, in USA, an unproven stem cell offering three elderly women were blinded after getting stem cells derived from fat tissue, at a clinic in Florida These factors are limiting the number of people opting for stem cell therapies, thus restraining the growth of the stem cell market. Companies in the stem cell therapeutics market are focusing on development of new technologies such as the Induced Pluripotent Stem Cells (IPSC) to boost the efficiency of stem cell therapies. IPSC are obtained from blood or skin cells that are reprogrammed to an embryonic-like pluripotent state by incorporating genes that are essential for maintaining key properties and growth of an unlimited source of any kind of human cell required for stem cell therapeutic purposes. These IPSC's are not derived from human embryos, which removes the bioethical issues, thus allowing scientists to obtain federal funding and support easily. A Japanese company, Oksara opened a medicine center that produced cells derived from iPS Cells. Similarly, Takar Bio company launched human iPSC derived Beta Cells i.e., Cellartis for disease modeling and drug discovery. The Food and Drug Administration's Centre for Biologics Evaluation and Research (CBER) is the regulator in the US, for human cells, tissues, and cellular and tissue-based products (HCT/P) intended for implantation, transplantation, infusion or transfer into a human recipient, including hematopoietic stem cells. There are certain protocols that the FDA has established, for example, the current good tissue practice, donor screening and donor testing requirements which are in place to prevent the transmission of any communicable diseases. The stem cells come from different sources (bone marrow, umbilical cord blood or peripheral blood) and have different applications. Licenses are required to distribute and market these products. In August 2021, Catalent, a US-based provider of advanced delivery technologies, development, and manufacturing solutions for pharmaceuticals, biologics, and cell and gene treatments acquired RheinCell Therapeutics GmbH for an undisclosed amount. With this acquisition Catalent aims to deploy RheinCell's expertise and deep knowledge in iPSC cell lines that will boost Catalent’s cell therapy portfolio, allowing them to offer iPSC banks to their customers as a premium source for their therapeutic development pathway. RheinCell Therapeutics GmbH is a Germany based company that specializes in the GMP-compliant generation of human induced pluripotent stem cells (iPS cells). North America was the largest region in the stem cell market in 2022. Western Europe was the second largest region in the global stem cell market share. The regions covered in the global stem cell market market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the stem cell market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The stem cell market consists of sales of organoids & 3D Cell Culture, mesenchymal Stem Cells, neural stem cells, hematopoietic stem cells, and cancer stem cells. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The stem cell market market research report is one of a series of new reports from The Business Research Company that provides stem cell market market statistics, including stem cell market industry global market size, regional shares, competitors with a stem cell market market share, detailed stem cell market market segments, market trends and opportunities, and any further data you may need to thrive in the stem cell market industry. This stem cell market market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Stem cell therapy refers to a form of regenerative medicine that uses stem cells or their byproducts to stimulate the body's natural repair process in damaged, malfunctioning, or wounded tissue. It is the next step in the transplantation of organs, replacing donor organs—which are scarce—with cells. The main types of stem cell therapy are allogeneic stem cell therapy and autologous stem cell therapy. Allogeneic stem cell transplantation involves transferring stem cells from a healthy person (the donor) to the patient's body after high-intensity chemotherapy or radiation. The various sources of the cells include adult stem cells, induced pluripotent stem cells, and embryonic stem cells that are used for the treatment of musculoskeletal disorders, wounds and injuries, cancer, autoimmune disorders, and others. The therapies are used by hospitals and clinics. The global stem cell therapy market is segmented – 1) By Type: Allogeneic Stem Cell Therapy, Autologous Stem Cell Therapy 2) By Cell Source: Adult Stem Cells, Induced Pluripotent Stem Cells, Embryonic Stem Cells 3) By Application: Musculoskeletal Disorders, Wounds and Injuries, Cancer, Autoimmune Disorders, Other Applications 4) By End-User: Hospitals, Clinics The global stem cell therapy market size will grow from $5.14 billion in 2022 to $6.45 billion in 2023 at a compound annual growth rate (CAGR) of 25.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global stem cell therapy market size is expected to grow to $11.88 billion in 2027 at a CAGR of 16.5%. The rising prevalence of chronic diseases contributed to the growth of the stem cell therapy market. Long working hours, limited physical activity, and unhealthy eating and drinking habits contribute to the prevalence of chronic diseases among people, thus driving the need for stem cell therapy. According to a United Nations article, by 2030, the proportion of global deaths due to chronic diseases is expected to increase to 70% of total deaths. The global burden of chronic diseases is expected to reach about 60%. The rising prevalence of chronic diseases is expected to drive the stem cell therapy market growth. Major players in the stem cell therapy market are Anterogen, JCR Pharmaceuticals, Medipost, Osiris Therapeutics, Pharmicell, Astellas Pharma, Cellectis, Celyad, Novadip Biosciences, Gamida Cell, Capricor Therapeutics, Cellular Dynamics, CESCA Therapeutics, DiscGenics, OxStem, Mesoblast, ReNeuron Group, Takeda Pharmaceuticals, Magellan, Kolon TissueGene, Stemedica Cell Technologies, Holostem Terapie Avanzate S.r.l., NuVasive, RTI Surgical and AlloSource. The high cost of stem cell therapy is expected to limit the growth of the stem cell therapy market. The pressure to contain costs and demonstrate value is widespread. Political uncertainty and persistent economic stress in numerous countries are calling into question the sustainability of public health care funding. In less wealthy countries, the lack of cost-effective therapies for chronic diseases has impacted the health conditions of the population and has led to a low average life expectancy. According to the DVCSTEM, the average cost of stem cell therapy in the USA is between $20,000 to $25,000, in Mexico, it is $33,000, in Central America, it is $30,000, and in Asia, it is $50,000, thus restraining the stem cell therapy market growth. The companies in the stem cell therapy market are increasingly investing in strategic partnerships. A strategic partnership is a mutually beneficial agreement between two companies that do not compete directly with each other. For instance, in June 2020, Shanghai Cell Therapy Group (SHCell) has recently begun a six-year research collaboration with Professor Qi-Long Ying of the University of Southern California (USC). The Ying laboratory hopes to develop conditions for long-term ex vivo expansion of mouse and human hematopoietic stem and progenitor cells through the project, which is supported by $3.6 million from the Baize Plan Fund. In July 2020, Boehringer Ingelheim, a Germany-based pharmaceutical company, acquired Global Stem Cell Technology (GST) for an undisclosed amount. The acquisition completely supports Boehringer Ingelheim's Animal Health strategy, which aims to improve its portfolio capabilities to spur innovation and growth. The purchase comes after a two-year, fruitful relationship that saw the introduction of the first-ever registered stem cell-based veterinary treatment to the European market. GST is a Belgian biotech company that develops and produces state-of-the art stem cell products for horses and pets. North America was the largest region in the stem cell therapy market in 2022. The Middle East is expected to be the fastest-growing region in the global stem cell therapy market during the forecast period. The regions covered in the global stem cell therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the stem cell therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The stem cell therapy market includes revenues earned by entities by hematopoietic stem cells, skin stem cells, neural stem cells, and mesenchymal stem cells. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The stem cell therapy market research report is one of a series of new reports from The Business Research Company that provides stem cell therapy market statistics, including stem cell therapy industry global market size, regional shares, competitors with a stem cell therapy market share, detailed stem cell therapy market segments, market trends and opportunities, and any further data you may need to thrive in the stem cell therapy industry. This stem cell therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Stem cells refer to cells which have the rare capacity to renew themselves and develop into specialized cell types. They act like the building blocks of all living things. Stem cell assay is developed for studying human stem cell growth to analyze the biological activities of stem cells in a controlled environment. The main types of stem cell assays market are cell viability and toxicity assays, cell apoptosis assays, cell function assays, cell identification assays, isolation and purification assays, cell differentiation assays, and others. Cell viability and cell toxicity assays are used to assess the physical and physiological well-being of cells in response to extracellular stimuli, chemical agents, medicinal treatments, or other situations, as well as when deciding on the best conditions for cell culture growth. The different products include instruments and detection kit that are used in several applications such as regenerative medicine and therapy development, drug discovery and development, and clinical research. The various end users are government research institutes, private research institutes, industry research. The global stem cell assay market is segmented - 1) By Type: Cell Viability And Toxicity Assays, Cell Apoptosis Assays, Cell Function Assays, Cell Identification Assays, Isolation And Purification Assays, Cell Differentiation Assay, Other Types 2) By Product: Instruments, Detection kit 3) By Application: Regenerative Medicine And Therapy Development, Drug Discovery And Development, Clinical Research 4) By End User: Government Research Institutes, Private Research Institutes, Industry Research The global stem cell assay market size grew from $1.57 billion in 2022 to $1.89 billion in 2023 at a compound annual growth rate (CAGR) of 20.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of global stem cell assay market is expected to grow to $4 billion in 2027 at a CAGR of 20.6%. The high prevalence of chronic diseases is expected to propel the growth of the stem cell assay market going forward. Chronic disease refers to an ailment or illness that often lasts for three months or longer and has the potential to worsen over time. Stem cells have the potential to treat a wide range of diseases, including chronic diseases. They help in the development of new antibodies and specialized cells that help to cure chronic diseases such as cancer. For instance, according to the Australian Bureau of Statistics, an independent statuary agency of the Australian government, in 2021, nearly 46.6% of Australians of all ages had one or more chronic diseases, and nearly one in five that is 20.7% had two or more chronic diseases. Therefore, the increase in the prevalence of chronic diseases is driving the growth of the stem cell assay market. Major players in the stem cell assay market are Thermo Fisher Scientific Inc., Merck Group, Danaher Corporation, Becton Dickinson and Company, Bio-Rad Laboratories, PerkinElmer, Agilent Technologies, Promega Biotechnology Company, Cell Biolabs, Miltenyi Biotec, STEMCELL Technologies, Bio-Techne Corporation, Charles River Laboratories International Inc., Hemogenix Inc., Lonza Group AG, Takara Bio Inc., Creative Bioarray, AAT Bioquest Inc., BPS Bioscience Inc., Enzo Biochem Inc., PromoCell, Biotium, Geno Technology, Abcam plc, and ReachBio Research Labs. Product innovations are the key trends gaining popularity in the stem cell assay market. Major companies operating in the stem cell assay market are introducing new products to sustain their position in the market. For instance, in May 2022, Beckman Coulter Life Sciences, a US-based healthcare company launched the AQUOS STEM System that helps to develop hematopoietic stem cells. This system helps to reduce hands-on time by 95% using an automated modular approach, error-prone processes are cut back by 87.5%, and turnaround times are shortened. The system runs on the AQUIOS CL Flow Cytometer that combines sample preparation and analysis in one compact platform. In July 2022, Fujifilm Cellular Dynamics Inc., a US-based manufacturer of human-induced pluripotent stem cell technologies, partnered with PhenoVista Biosciences. This partnership will help drug discovery researchers to access services for high content screening imaging using iPSC-derived differentiated cells to help in the drug discovery process. PhenoVista Biosciences is a US-based company that provides imaging-based phenotypic assay services for drug discovery using induced pluripotent stem cell (iPSCs) in screening. North America was the largest region in the stem cell assay market share in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the global stem cell assay industry report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the stem cell assay market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The stem cell assay market consists of sales of tetrazolium reduction assays, resazurin cell viability assays, calcein-AM cell viability assays, proliferation assays, differentiation assays, function assays, caspase assays and annexin v and cell permeability assays. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The stem cell assay market research report is one of a series of new reports from The Business Research Company that provides stem cell assay market statistics, including stem cell assay industry global market size, regional shares, competitors with an stem cell assay market share, detailed stem cell assay market segments, market trends and opportunities, and any further data you may need to thrive in the stem cell assay industry. This stem cell assay market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Induced pluripotent stem cells are the regenerated form of stem cells, which are produced from an existing adult cell, such as from hepatocytes, fibroblasts, keratinocytes, and neurons. The main derived cell types of induced pluripotent cells are hepatocytes, fibroblasts, keratinocytes, amniotic cells, and others. Hepatocytes are the liver's primary functional cells, performing a staggering array of metabolic, endocrine, and secretory tasks. The various application includes academic research, drug development, and discovery, toxicity screening, and regenerative medicine and are used in several sectors such as hospitals, and research laboratories. The global induced pluripotent stem cell (iPSC) market is segmented - 1) By Derived Cell Type: Hepatocytes, Fibroblasts, Keratinocytes, Amniotic Cells, Other Derived Cells 2) By Application: Academic Research, Drug Development And Discovery, Toxicity Screening, Regenerative Medicine 3) By End-User: Hospitals, Research Laboratories The global induced pluripotent stem cell (ipsc) market size will grow from $2.69 billion in 2022 to $2.97 billion in 2023 at a compound annual growth rate (CAGR) of 10.5% . The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the global induced pluripotent stem cell (ipsc) market is expected to grow to $4.36 billion in 2027 at a CAGR of 10.1% . An increase in the prevalence of chronic disorders is one of the major factors that is driving the growth of the Induced pluripotent stem cell market. Chronic disorders like heart disease, cancer, stroke, diabetes can be treated with Induced pluripotent stem cell. Induced Pluripotent stem cells are taken from any tissues from a child or an adult and are genetically modified to behave like embryonic stem cells. According to the report published by Partnership to Fight Chronic Disorder (PFCD), it was found that out of 133 million Americans, 45% of the population had at least one chronic disorder. Moreover, it was estimated that 7 out of 10 deaths in the USA, which is approximately 1.7 million, are due to chronic disorders and these deaths can be controlled by induced pluripotent stem cell treatment. This rise in incidences of chronic diseases is driving the demand for induced pluripotent stem cell treatment market. Major players in the induced pluripotent stem cell (iPSC) market are Thermo Fisher Scientific Inc., FUJIFILM Holdings Corporation (Cellular Dynamics), Takara Bio Inc., Astellas Pharma Inc., Fate Therapeutics, ViaCyte, StemCells, Japan Tissue Engineering Co. Ltd., Fate Therapeutics and Japan Tissue Engineering Co . The potential risk of tumour is one of the major restraints on the growth of the Induced pluripotent stem cell market. As per a scientific research, it was found that there might be a chance of getting cancer from the treatment and people are unwilling to take treatment through Induced pluripotent stem cell therapy. According to the report by American Association for cancer research, in most of the cases while doing the experiment it was found that the occurrence of the tumours was prevalent after a short period of time. This risk of developing a tumour due to Induced pluripotent stem cell therapy is limiting the number of patients opting for this treatment, thereby restraining the growth of the market. Companies in the Induced Pluripotent stem cell market are looking for opportunities for strategic partnerships and collaborations that will help these companies to enter into new geographies and to expand product portfolios. For example, in January 2022, Bristol Myers Squibb and Century Therapeutics entered into a strategic collaboration to develop iPSC-derived allogenic cell therapies for the treatment of acute myeloid leukemia and multiple myeloma. Furthermore, in May 2022, Evotec and Sernova announced strategic partnership to develop iPSC-based beta cell replacement therapy for treatment for type 1 and type 2 diabetes. National Institute of Health (NIH), a part of Department of Health and Human Services, regulates the market for Induced Pluripotent stem cells (iPSC) in the US. If a company is using, making or planning to acquire iPSCs, they are required to provide some information. For instance, a complete and signed copy of the IPSC checklist must be submitted. Any acquisitions in the IPSC’s must obtain approval from the Institutional review board (IRB), the signed approval documents must be attached to the checklist. If the IPSC lines are purchased from an outside or commercial source these agreement documents must also be attested by the IRB and attached. The IPSC’s must be generated by the Intramural Research Program (IRP) under a signed contract before they can be used for any further experimentation. In August 2021, catalant, a Us-based pharmaceutical company, acquired RheinCell Therapeutics GmbHfor an undisclosed amount. The acquisition will help Catalent to grow in the cell and gene therapy vertical and develop therapies based on induced pluripotent stem cells. RheinCell Therapeutics GmbH is a Germany-based developer of human induced pluripotent stem cells (iPSCs) for next generation cell therapies. North America was the largest region in the induced pluripotent stem cell (iPSC) market in 2022. Western Europe was the second largest region in the global induced pluripotent stem cell (iPSC) market share. The regions covered in the global induced pluripotent stem cell (iPSC) market report analysis are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the induced pluripotent stem cell (iPSC) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The induced pluripotent stem cell (iPSC) market consists of sales of induced pluripotent stem cells and related services. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The induced pluripotent stem cell (iPSC) market research report is one of a series of new reports from The Business Research Company that provides induced pluripotent stem cell (iPSC) market statistics, including induced pluripotent stem cell (iPSC) industry global market size, regional shares, competitors with an induced pluripotent stem cell (iPSC) market share, detailed induced pluripotent stem cell (iPSC) market segments, market trends and opportunities, and any further data you may need to thrive in the induced pluripotent stem cell (iPSC) industry. This induced pluripotent stem cell (iPSC) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Neurodegenerative disorder therapeutics refer to a medication or gene therapy to treat patients with neurodegenerative disorders therapeutically by directly rectifying pathogenic pathways, through neuroprotection, neurorestoration, and symptom control. The main drug types of neurodegenerative disorder therapeutics are n- methyl- d- aspartate receptor, selective serotonin reuptake inhibitor, dopamine inhibitors, and others. Selective serotonin reuptake inhibitors are a type of medication that is commonly used to treat depression and a few other mental illnesses. The various indications include Parkinson’s disease, Alzheimer’s disease, multiple sclerosis, Huntington’s disease, and other indications that ARE distributed through hospital pharmacy, retail pharmacy, and online pharmacy. The global neurodegenerative disorder therapeutics market is segmented - 1) By Indication Type: Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis, Huntington Disease, Other Indication Types 2) By Drug Type: N- methyl- D- aspartate Receptor, Selective Serotonin Reuptake Inhibitor, Dopamine Inhibitors, Other Drug Types 3) By Distribution: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy The global neurodegenerative disorder therapeutics market size grew from $15.86 billion in 2022 to $17.14 billion in 2023 at a compound annual growth rate (CAGR) of 8.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the neurodegenerative disorder therapeutics is expected to grow from $23.65 billion in 2027 at a CAGR of 8.4%. Increased prevalence of neurodegenerative among the global population contributes to the growth of the neurodegenerative disorder therapeutics market. The increase in the geriatric population attributes to the increased prevalence of neurodegenerative disorders. According to World Population Prospects, the number of people above 60 years of age will increase to 2.1 billion in 2050 and it is expected that people aged over 80 years will triple to 425 million in 2050. According to the Alzheimer’s Association, around 5.8 million Americans are suffering from Alzheimer’s disease, and this number is projected to rise to around 14 million by 2050. The increased prevalence of neurodegenerative diseases among the aging population increases the demand for neurodegenerative disorder therapeutics thereby driving the neurodegenerative disorder therapeutics market. Major players in the neurodegenerative disorder therapeutics market are Biogen, Pfizer, Novartis, Sanofi, Teva Pharmaceutical, UCB, Hoffmann- La Roche Ltd., ACADIA Pharmaceuticals Inc., Lundeck A/S, Boehringer Ingeiheim International GmbH, Merck Serono, Orion Pharma Ltd., Mitsubishi Tanabe Pharma America, Allergan, GlaxoSmith Kline PLC., AbbVie, Eli lilly, Celgene, Neuro- Hitech Inc., Bayer Schering Pharma AG, Amarin Corporation, AstraZeneca, Alector, Yumanity Therapeutics, Yangtze River Pharmaceutical Group, Chongqing Zein Pharmaceutical and Eisai. High rates of failure in clinical trials and research and development (R&D) have always been a major challenge in the neurodegenerative disorder therapeutics market. Companies are continuously investing in R&D to develop treatments for neurodegenerative diseases but currently, very few treatments are approved for neurodegenerative disorders. According to a study in 2019, there are officially 112 new molecular entities in Alzheimer’s disease (AD) clinical trials, although there are 3558 in cancer trials. For instance, 12 of the 42 (28 percent) drugs certified by the US Food and Drug Administration (FDA) were oncology therapies, this compares with 0% of AD drugs in production. This failure entitled Alzheimer’s disease drugs to the highest rates of failure at 99.6% when compared to any other disease, including cancer, which has a failure rate of 81%. Moreover, as reported by The New England Journal of Medicine, no new drug has been approved by the Food and Drug Administration (FDA) to treat Alzheimer’s disease since 2013. The low rate of approval of neurodegenerative therapeutics hurts the market, hindering its growth of the neurodegenerative disorder therapeutics market. Manufacturers of neurodegenerative disorder therapeutics are undergoing various strategic partnerships with government and non-government organizations to discover and develop therapeutics for a range of neurodegenerative diseases. The companies in the neurodegenerative disorder therapeutics market are also increasing their collaboration with other players in the market to increase their capabilities for research and development activities to develop new and more effective therapeutic solutions to treat neurodegenerative disorders. For instance, in July 2022, NRG Therapeutics, a UK-based drug discovery company focussed on therapeutic approaches, partnered with Domainex, a UK-based drug discovery service, to develop neurodegenerative disease treatment. For the treatment of Parkinson's disease, motor neurone disease (MND), and other incapacitating chronic neurodegenerative conditions, the firms would work together to develop novel small molecule disease-modifying medications. In January 2020, Biogen Inc., an American biotechnology company, paid $75 million for a novel clinical-stage asset, PF-05251749, as well as the applications from Pfizer.The acquisition of the asset is expected to strengthen Biogen’s existing pipeline of potential disease-modifying therapies in Alzheimer’s and Parkinson’s diseases since PF-05251749 is a CNS-penetrant regulator that has the potential to treat behavioural and neurological symptoms across various psychiatric and neurological diseases. Pfizer Inc. is a multinational pharmaceutical company based in the USA. North America was the largest region in the global neurodegenerative disorder therapeutics market in 2022. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the global neurodegenerative disorder therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the neurodegenerative disorder therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The neurodegenerative disorder therapeutics market includes revenues earned by entities by correction of pathogenic mechanisms, neuroprotection, neurorestoration, and symptom control. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The neurodegenerative disorder therapeutics market research report is one of a series of new reports from The Business Research Company that provides neurodegenerative disorder therapeutics market statistics, including neurodegenerative disorder therapeutics industry global market size, regional shares, competitors with a neurodegenerative disorder therapeutics market share, detailed neurodegenerative disorder therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the neurodegenerative disorder therapeutics industry. This neurodegenerative disorder therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Regenerative medicine for cartilage refer to a medication used during surgery to repair damaged cartilage in the knees using body-produced cells that can create cartilage. A biopsy is required to collect chondrocytes (cells that produce cartilage), which are then multiplied in a lab before being implanted into the injured area during surgery. The main types of regenerative medicine for cartilage are cell-based and non-cell-based. The type of treatment includes palliative and intrinsic repair stimulus among others that are used by ambulatory surgical centers, hospitals and clinics, and surgical centers. The regenerative medicine for cartilage is used for hyaline cartilage repair and regeneration, elastic cartilage repair and regeneration, and fibrous cartilage repair and regeneration. The global regenerative medicine for cartilage market is segmented - 1) By Treatment Modality: Cell-Based, Non-Cell-Based 2) By Treatment Type: Palliative, Intrinsic Repair Stimulus, Other Treatment Types 3) By Site: Knee Cartilage Repair, Ribs, Other Sites 4) By Application: Hyaline Cartilage Repair and Regeneration, Elastic Cartilage Repair and Regeneration, Fibrous Cartilage Repair and Regeneration 5) By End-Use: Ambulatory Surgical Centers, Hospitals & Clinics, Surgical Centers, Other End-Users The global regenerative medicine for cartilage market size will grow from $5.28 billion in 2022 to $5.82 billion in 2023 at a compound annual growth rate (CAGR) of 10.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the regenerative medicine for cartilage is expected to grow to $7.72 billion in 2027 at a CAGR of 7.3%. The growing incidence of osteoarthritis across the globe will drive the regenerative medicine for cartilage market. Osteoarthritis is a degenerative joint disorder that mostly attacks the articular cartilage. According to the Arthritis Foundation, degenerative joint disease disorders such as osteoarthritis will impact at least 130 million individuals around the globe by 2050. Some of the most commonly used treatments for osteoarthritis are autologous chondrocyte implantation and scaffold implants. Thus, the increasing incidence of osteoarthritis is expected to drive the demand for growth of the regenerative medicine for cartilage market. Major players in the regenerative medicine for cartilage market are B. Braun Melsungen AG, Zimmer Biomet Holdings Inc., Vericel Corporation, Stryker Corporation, Smith & Nephew PLC, Arthrex Inc., CONMED Corporation, Collagen Solutions PLC, BioTissue Technologies, CellGenix, Osiris Therapeutics Inc., and DePuy Synthes. The high cost of regenerative medicine therapies is one of the major factors limiting the growth of the market for regenerative medicine for cartilage. The average cost for knee replacement is around $4,500 to $8,400, while the average cost of cartilage repair procedures is around $18,000, depending on the country where the procedure is being performed. Such high prices discourage individuals to resort to cartilage repair therapies and, in turn, result in a lower preference for these procedures. Tissue engineering and stem cell therapy are emerging trends in regenerative medicine for the cartilage market. The growth of tissue engineering technology has given hope for the regeneration of cartilage. Stem cell therapy is gaining attention with its advantages over traditional orthopaedic treatments. Stem cell therapy helps to reduce knee pain and improves knee cartilage regeneration and repair. For instance, growth factors in the form of platelet-rich plasma (PRP) therapy are injected to promote tissue regeneration effectively. Companies operating in the market are continuously focusing on introducing new technologies to survive in the regenerative medicine for cartilage market. In September 2020, Smith & Nephew plc, a UK-based multinational medical equipment manufacturing company, acquired the orthopaedics business of Integra LifeSciences Holdings Corporation for an amount of $240 million. The acquisition is expected to stimulate growth in Smith & Nephew’s extremities business by adding a targeted sales channel, a portfolio of compatible upper and lower extremities, shoulder replacements, and an intriguing new product pipeline. Integra LifeSciences Holdings Corporation is a US based medical device manufacturing company specializing in solutions in extremities orthopedics, neurosurgery, and regenerative technologies, all geared toward reducing clinician uncertainty. Europe was the largest region in regenerative medicine for cartilage in 2022. The regions covered in the regenerative medicine for cartilage market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the regenerative medicine for cartilage market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The regenerative medicine for cartilage market consists of sales of cartilage regeneration, platelet-rich plasma (PRP), and prolotherapy. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The regenerative medicine for cartilage market research report is one of a series of new reports from The Business Research Company that provides regenerative medicine for cartilage market statistics, including regenerative medicine for cartilage industry global market size, regional shares, competitors with a regenerative medicine for cartilage market share, detailed regenerative medicine for cartilage market segments, market trends and opportunities, and any further data you may need to thrive in the regenerative medicine for cartilage industry. This regenerative medicine for cartilage market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Digital diabetes management refers to using electronic medical solutions to monitor, analyze, and manage diabetics remotely. People with diabetes or those who are at risk for developing it can improve their health outcomes by successfully managing their condition on their own with the help of digital diabetes management. The main types of products and services in digital diabetes management are devices, application, data management software & platforms, services. A data management platform (DMP) is a piece of software that collects and manages data. They enable companies to create audience segments that can then be utilized to target certain individuals and settings in online advertising campaigns. The different types of devices include handheld devices, wearable devices and used in various sectors such as self or home healthcare, hospitals and specialty diabetes clinics, others. The global digital diabetes management market is segmented - 1) By Product & Service: Devices, Application, Data Management Software & Platforms, Services 2) By Device Type: Handheld Devices, Wearable Devices 3) By End User: Self/Home Healthcare, Hospitals & Specialty Diabetes Clinics, Other End Users The global digital diabetes management market size will grow from $10.82 billion in 2022 to $13.25 billion in 2023 at a compound annual growth rate (CAGR) of 22.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of global digital diabetes management is expected to grow to $30.11 billion in 2027 at a CAGR of 22.8%. The increasing prevalence of diabetes is projected to propel the demand for digital diabetes management devices and related services, thereby increasing the demand for the market. Diabetes is a leading cause of death, with 30% of loss of life expectancy coming from the diagnosis of diabetes. In 2021, according to the International Diabetes Federation, a total of 537 million individuals (20-79 years old) worldwide had diabetes and according to projections, there will be 643 million diabetics worldwide by 2030 and 783 million by 2045. Major players in the digital diabetes management market are Bayer AG, Medtronic, Roche Diagnostics, Dexcom, Inc., Abbott Laboratories, Ascensia Diabetes Care, Insulet Corporation, B. Braun Melsungen AG, Tandem Diabetes Care and LifeScan Inc. Data security is a major challenge limiting the growth of the digital diabetes management market. Data safety is necessary to maintain integrity and confidentiality. A lack of accurate flow of information and commands is likely to compromise the function of digital diabetes devices and may put patients or users at the risk of health complications. For instance, according to Hippa Journal, the official publication of the American Health Information Management Association, the Office for Civil Rights (OCR) of the Department of Health and Human Services (HHS) received 347 reports of healthcare data breaches involving 500 or more records between January 1, 2022, and June 30, 2022. Several companies are increasing attention on developing design-focused and AI-powered connected apps to enhance the user experience, which is gaining significant popularity in the digital diabetes management market. Key companies operating in the digital diabetes management market including OneDrop, Ascencia, and Dario are increasing their focus on developing their products as stylish gadgets rather than medical devices. For instance, Medtronic plc and IBM Watson Health announced the launch of AI-powered Sugar.IQ smart diabetes management app, designed to improve and simplify daily diabetes management. In April 2020, OneDrop, a consumer diabetes management platform, announced the acquisition of assets, IP, and certain staff of Sano Intelligence Inc., an innovator in health sensing technology, for an undisclosed amount. OneDrop and Sano Intelligence shared a vision of transforming traditional healthcare into preventive and proactive self-care. The companies are expected to integrate Sano’s silicon sensing technology into a painless silicon-based health sensing platform for use across multiple conditions, which is a personalized solution for a rapidly growing health issue. Sano Intelligence, Inc. was founded in 2011 and is a manufacturer of non-invasive connected CGM patch. North America was the largest region in the digital diabetes management market in 2022. Western Europe was the second largest region in the digital diabetes management market report. The regions covered in the digital diabetes management industry report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the digital diabetes management market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The digital diabetes management market consists of revenue generated by the companies offering devices and services that manage blood glucose levels in the human body. These devices play a vital role in the care of diabetes patients with the management of patients' blood glucose levels and controlling their conditions. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The digital diabetes management market research report is one of a series of new reports from The Business Research Company that provides digital diabetes management market statistics, including digital diabetes management industry global market size, regional shares, competitors with a digital diabetes management market share, detailed digital diabetes management market segments, market trends and opportunities, and any further data you may need to thrive in the digital diabetes management industry. This digital diabetes management market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Diabetes care devices are used to monitor and control blood glucose levels in diabetic patients. The main types of diabetes care devices are blood glucose test strips, insulin pens, syringes, pumps and injectors, lancing devices and equipment, continuous glucose monitoring devices and equipment, and blood glucose meters. Insulin pens are injection devices with a needle that delivers insulin into the subcutaneous tissue. The type of expenditures is public and private. The products used are instruments/equipment and disposables. The various end-users are hospitals and clinics, diagnostic laboratories, and others. The global diabetes care devices market is segmented - 1) By Type: Blood Glucose Test Strips, Insulin Pens, Syringes, Pumps And Injectors, Lancing Devices And Equipment, Continuous Glucose Monitoring Devices And Equipment, Blood Glucose Meters 2) By End User: Hospitals And Clinics, Diagnostic Laboratories, Other End Users 3) By Type of Expenditure: Public, Private 4) By Product: Instruments/Equipment, Disposables Subsegments Covered: Glucose Dehydrogenase, Glucose Oxidase, Pens, Injectors And Pumps, Syringes The global diabetes care devices market size will grow from $58.63 billion in 2022 to $62.94 billion in 2023 at a compound annual growth rate (CAGR) of 7.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of global diabetes care devices is expected to grow to $80.06 billion in 2027 at a CAGR of 6.2%. Busy lifestyles and changing consumer preferences are affecting the disease profile of the world population, especially non-communicable diseases such as diabetes. Long working hours, limited physical activity, and unhealthy eating and drinking habits are major causes of diabetes. For instance, according to WHO data 2021, more than 95% of people with diabetes have type 2 diabetes. According to a World Health Organization (WHO) report, 74% of men and 64% of women in the UK, for instance, are expected to be overweight by 2030. These factors are expected to increase the patient pool of diabetes. For instance, according to IDF data 2021, nearly 537 million adults (20-79 years) are living with diabetes. The total number of people living with diabetes is projected to rise to 643 million by 2030 and 783 million by 2045. These factors are expected to aid the growth of the diabetes care devices market in the forecast period. Major companies in the diabetes care devices market include Abbott Laboratories, Novo Nordisk, Medtronic Inc., Dexcom, Inc., F. Hoffmann-La Roche Ltd., Becton Dickinson, Insulet, Ypsomed, ConvaTec Group Plc, and B. Braun Group. The diabetes care devices market is expected to be limited by the high cost of the equipment, especially in low-income countries, where the cost related to diabetes devices is very high, despite insurance coverage. For example, in the US all the expenses related to diabetes treatment, which includes diabetes care devices can reach $1,000 a month. Thus, high costs associated with diabetes care devices and their accessories are likely to impede the market growth going forward. Pharmaceutical companies are investing in developing and commercializing glucose-responsive insulins (GRIs), providing significant opportunities for the development of new types of insulin delivery devices. For example, Novo Nordisk, a Danish pharmaceutical company, has planned to develop GRIs by acquiring UK biotech start-up Ziylo with an investment of $800 million. Companies such as Eli Lily and Sanofi have also planned research projects to develop GRIs. GRIs are 'smart' insulins that automatically activate or deactivate in response to changing glucose levels in the blood. They improve diabetes treatment efficacy and reduce the incidence of hyperglycemia and hypoglycemia. North America was the largest region in the global diabetes care devices market in 2022. Western Europe was the second largest region in the global diabetes care devices market share. The regions covered in the diabetes care devices market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the diabetes care devices market report are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa., South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela, and Vietnam. The diabetes care devices market consists of sales of blood glucose monitoring devices, insulin delivery devices, smart insulin pens and others that are used for monitor and treat diabetes patient. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The diabetes care devices market research report is one of a series of new reports from The Business Research Company that provides diabetes care devices market statistics, including diabetes care devices industry global market size, regional shares, competitors with a diabetes care devices market share, detailed diabetes care devices market segments, market trends and opportunities, and any further data you may need to thrive in the diabetes care devices industry. This diabetes care devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.